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ABSTRACT
Osteoarthritis (OA) is the most com-
mon form of arthritis. Pain and its 
related function and stiffness are cur-
rently the major symptoms and primary 
outcomes for treatment. However, the 
treatment in the past has been primar-
ily targeting on the peripheral changes 
in the joint that has led to suboptimal 
outcomes. Recently, we find that peo-
ple with OA respond better to treatment 
which targets on both peripheral and 
central pain abnormalities. We also 
find that placebo per se is very effec-
tive for OA. On average 75% pain re-
duction, 71% functional improvement 
and 83% stiffness improvement in the 
treatment of OA are attributable to the 
placebo/contextual effect. The effect 
varies between treatments, for example 
for pain, from 47% with intra-articular 
corticosteroid injection to 91% with 
joint lavage. This begs a question on 
how to improve the overall treatment 
effect of an OA therapy in clinical 
practice by enhancing the contextual 
effect, rather than to separate a specif-
ic treatment effect from the contextual 
effect as we normally do in clinical tri-
als. The enhancement may be achieved 
by improving contextual factors such 
as patient-physician interaction or 
quality of care. Further research on 
the development of a simple contextual 
enhancement package that may be de-
livered by all physicians according to 
individual needs would be very helpful.
Osteoarthritis 
About one in four people aged 55 years 
have knee pain related to osteoarthritis 
(OA) of whom one in ten have disabil-
ity (1). Half of us would develop knee 
OA if we all could live for 85 years (2). 
Both the incidence and prevalence of 
OA increase with age and are greater 
in women than men (3). Important risk 
factors for OA, in addition to age and 
female gender, include obesity (4), knee 
injury (5) and occupation (e.g. heavy 
lifting and professional sporting) (6). 
New risk factors identified more recent-
ly such as shape of hips (7), malalign-
ment of knees (8), finger length ratio 
(2d4d ratio) (9) and genes (10, 11) may 
add to understanding of pathogenesis. 
OA may be diagnosed clinically or ra-
diographically (12). It is suggested that 
a confident clinical diagnosis of knee 
OA can be made based on 3 symptoms 
(pain on usage, short-lived morning 
stiffness and functional limitation) and 
3 signs (crepitus, restricted movement 
and bony enlargement) without radio-
graphic examination (12). 
 
Treatments of OA
More than 50 treatments have been de-
veloped for OA, the majority of which 
are symptomatic therapies (13). The 
beneficial effects of these treatments 
are marginal, with an average effect 
size (ES) of 0.31 (95% confidence in-
terval (CI) 0.23, 0.39) (13). The bene-
fits often are outweighed by the adverse 
effects (13). For example, paracetamol 
(acetaminophen) is currently recom-
mended the first line analgesic for OA. 
However, its ES for pain is only 0.14 
(95%CI 0.05, 0.23), which does not 
reach the threshold of the minimum 
clinical importance difference (MCID) 
of ES of 0.5 recommended by the Na-
tional Institution of Health and Care for 
Excellence (NICE) (14). In contrast its 
side effects could be substantial (15). A 
population-based study in Canada dem-
onstrated that paracetamol at 3g/day 
or more was associated with 20% in-
creased risk (relative risk=1.20, 95%CI 
1.03, 1.40) of the hospitalisation due 
to gastrointestinal (GI) complications 
(16). A further population-based study 
in the UK General Practice Research 
Database (GPRD) showed that par-
acetamol was associated with an in-
creased risk of upper gastrointestinal 
(GI) bleeding, myocardial infarction 
(MI), stroke, heart failure, renal failure 
and all cause death. The risk profile was 
similar to ibuprofen it was and dose-
dependent (17). 
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It is well known that non-steroidal 
anti-inflammatory drugs (NSAIDs) are 
associated with GI and cardiovascular 
(CV) adverse events. In the US, for ex-
ample, more than 16,500 deaths from 
GI bleeding are associated with the use 
of NSAIDs (18). In the UK, over 2,000 
people die annually from NSAID-in-
duced GI bleeding, which is the third 
leading cause of death (ovarian can-
cer, road accidents and NSAIDs…) 
(19). More than 2 billion dollars are 
spent annually to treat NSAID com-
plications in the US (18), that means 
for every dollar spent on NSAIDs, ap-
proximately one more dollar is spent on 
treating NSAID-induced complications 
(18). Furthermore, NSAIDs are associ-
ated with increased CV adverse events. 
Current evidence confirm that the CV 
adverse events are not only associated 
with COX-2 inhibitors (coxibs) but also 
with conventional NSAIDs (15). 
Safer agents such as glucosamine and 
chondroitin products have been devel-
oped. However, like many other nu-
traceuticals, the efficacy remains con-
troversial (15). Non-pharmacological 
therapies (e.g. exercise) are currently 
the core therapies for OA. However, 
many patients require more than only 
exercise in order to control pain and 
functional disability (14, 20). While the 
development of new treatments is im-
portant, less has been done on optimisa-
tion of the current treatments according 
to the context of therapy and individual 
responses.
Suokas and colleagues recently dem-
onstrated that OA was not simply a 
peripheral joint disease, but a condi-
tion related to the central sensitisation 
(21). It is well known that OA pain 
often is discordant with the underly-
ing structure damages (22, 23). People 
with severe radiographic OA may not 
have symptoms, whereas those with 
very minor radiographic OA may com-
plain more. OA also is associated with 
an increased likelihood of other joint 
pain (e.g. chronic widespread pain syn-
drome) (24). Persistent knee pain re-
mains in some patients after total knee 
replacement (TKR) (25). 
I have therefore proposed that the treat-
ment should be tailored to the disease 
stage according to contributions from 
central and peripheral pain mechanisms 
and patient characteristics (Fig. 1). For 
example, at the early stage of knee 
OA pain, strengthening exercise and/
or topical NSAIDs may be more use-
ful due to the main contribution from 
peripheral risk factors at this stage. At 
the middle stage of the disease, mind-
body exercise and/or intra-articular 
corticosteroid injection (stronger anal-
gesic with greater placebo effect) may 
be more useful because of contribu-
tions from both central and peripheral 
risk factors. At the later stage or even 
after TKR, mindfulness (or meditation) 
and/or central analgesics such as dulox-
etine or opioids may be more useful, 
as central pain mechanism may play a 
major role at this stage. This proposed 
approach is subject to individual patient 
characteristics and is supported by our 
current research in knee pain, in which 
peripheral risk factors contributed more 
to the incidence of knee pain whereas 
central risk factors contributed more to 
the progression of knee pain (26). It is 
also supported by the lesson we have 
learnt recently that biologic agents for 
OA were no better than placebo if they 
were used, irrespective of the disease 
stage and individual patient character-
istics (27). The treatment for OA pain 
should consider both peripheral and 
central pain mechanisms.
Placebo 
Treating both peripheral and central 
pain abnormalities is not easy with 
drugs. It often requires combinations of 
two or more drugs for different sites of 
the pain pathway. Such combinations 
often cause more side effects, hence 
have limitations. In contrast, exercise 
is a unique therapy which may be de-
livered in different forms for multiple 
benefits (Fig. 1). Placebo is another 
treatment with such multiple benefits, 
but has been largely ignored because of 
ethical issues and controversial results 
from a mega-meta-analysis in over 60 
conditions (28). 
Placebo is defined as a substance or 
procedure… that is objectively without 
specific activity for the condition be-
ing treated (29). It is unethical to use 
an inert pill to treat patients if we know 
it contains no active ingredient. How-
ever, is it truly ineffective? Irrespective 
of the inadequate amalgamation of the 
different conditions which respond to 
placebo differently, the meta-analysis 
reported by Hrobjartsson et al. in fact 
confirmed that placebo was more ef-
fective than no treatment for pain (28). 
This is in line with Beecher’s previ-
ous findings in terms of the placebo 
response (change from baseline in the 
placebo group) in the late 1950s (30), 
but more specific for the difference be-
tween placebo and no treatment group. 
It is further supported by recent ran-
domised controlled trials (RCTs) where 
placebo has been compared with no 
treatment or waiting list control in com-
mon cold, hypertension, irritable bowel 
syndrome and OA (31-34). 
Whether placebo works or not is no 
longer a question. How it works or what 
are the key contextual elements that 
make placebo work becomes a research 
agenda at the moment. From its initial 
use to please patients in the 1700s (31-
35) to the first placebo-controlled RCT 
published in 1948 (36) and now back 
to clinical practice as a contextual en-
hancement therapy, an oldest treatment 
in the medical history faces a new era 
(Fig. 2). 
Placebo effect in OA
In 2008, we undertook a meta-analysis 
of RCTs to examine whether placebo 
was effective and analysed its possible 
determinants in OA (37). A system-
atic literature search was conducted to 
search randomised, placebo/untreated 
control trials in OA. Efficacy data in 
pain, function, stiffness and global as-
sessment, as well as walking distance, 
muscle strength, range of movement, 
etc. were extracted from each relevant 
trial. 
Effect size (ES) was calculated as the 
mean difference from baseline to end-
point for each treatment arm. ES was 
compared between placebo and un-
treated arm to establish the placebo ef-
fect. Publication bias was determined 
using the funnel plot and the Eggers 
test. Heterogeneity was examined us-
ing the forest plot and the I2 statistics. 
Subgroup and mete-regression analy-
ses were undertaken to examine the de-
terminants of the placebo effect.
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Over 4000 studies were obtained from 
the search. After the scrutiny, 198 met 
the inclusion criteria, of which 184 
with placebo, 3 with both placebo and 
untreated control and 11 with untreated 
control. The funnel plot demonstrated 
an asymmetric distribution, suggesting 
that the studies with smaller placebo 
effect are more likely to be published. 
This finding is in accordance with other 
evidence that the studies with a positive 
result for the new treatment (i.e. differ-
ence between active and placebo treat-
ment) is more likely to be published. 
The overall ES of placebo was 0.51 
(95%CI 0.47, 0.56) for pain, which was 
significantly better than no treatment 
(ES 0.03, 95%CI -0.03, 0.18) (37), sug-
gesting placebo is effective to relieve 
pain due to OA. The placebo effect 
increased with strength of active treat-
ment, baseline pain score and sample 
size. Needle placebo was more effec-
tive than pill placebo. The study also 
found that placebo was effective for 
function, stiffness and physician global 
assessment, but not significantly for 
muscle strength, knee circumference, 
and range of movement (Table I).
Contextual effect of treatment 
Placebo effect is in fact an integral part 
of treatment effect. It can never be or 
need not be separated from treatment 
effect in clinical practice. The separa-
tion is only needed when we do a RCT 
to develop a new treatment. In clinical 
practice, however, the separation be-
comes redundant. It has developed a 
gap between trial and clinical practice, 
i.e. what we get from RCTs is often dif-
ferent from what we observe in clinical 
practice, so called “efficacy paradox” 
(38). For example, intra-articular hya-
luronic acid (IAHA) is no better than 
placebo in RCTs; therefore, we do not 
recommend IAHA for OA. In contrast, 
NSAIDs are better than placebo in 
RCTs; hence we recommend the use of 
NSAIDs for OA (with PPIs as appropri-
ate to reduce NSAIDs-induced GI ad-
verse effects) (14). However, in clinical 
practice, what we have observed is the 
total treatment effect that includes both 
specific treatment effect and the con-
textual (or placebo) effect, from which 
IAHA is better than NSAIDs (Fig. 3)! 
These observations have made clini-
cians confused and many do not trust 
the guidelines. We have therefore 
proposed a measure to overcome this 
paradox – proportion of the contextual 
effect (PCE) (39). The PCE can be sim-
ply calculated from a trial with placebo 
response (e.g. change from baseline 
in placebo group) divided by overall 
Fig. 1. Central 
and peripheral 
contributions to 
pain at different 
stages of knee os-
teoarthritis and op-
timal treatments. 
Fig. 2. Brief history and terminology of placebo. 
Table I. Placebo effect for different outcomes in osteoarthritis. Adapted from Zhang et al.: Ann Rheum Dis 2008; 67: 1716-23 with permission.
Outcomes  no. of studies no. of patients  ES 95%CI Chi-square p-value
     (heterogeneity)  (heterogeneity)
Pain  180 14686 0.51 0.46, 0.55 555.31 <0.001
Function 80 8289 0.49 0.44, 0.54 180.81 <0.001
Stiffness 72 7529 0.43 0.38, 0.49 150.22 <0.001
Physician global assessment 21 3459 0.66 0.53, 0.78 113.29 <0.001
Walking time/distance 11 526 0.22 0.08, 0.35 11.87 0.29
Quadriceps strength 2 35 -0.24 -0.72, 0.23 0.58 0.45
Joint space width 5 458 0.32 0.17, 0.46 4.58 0.33
Knee circumference 2 65 0.45 -0.21, 1.10 6.23 0.04
Range of motion 3 134 0.04 -0.36, 0.43 0.83 0.66
ES: effect size, CI: confidence interval. 
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treatment response (e.g. change from 
baseline in treatment group). In OA, for 
example, on average, the PCE is 0.75 
for pain, which means 75% pain relief 
effects are explained by the contextual 
effects. The PCE varies between treat-
ments from 47% for intra-articular cor-
ticosteroid (IACS) injection to 91% for 
lavage on pain outcome (Fig. 4) (39). 
The PCE varies between outcomes, 
which is 0.71 for function, suggesting 
that 71% improvement in function are 
in fact obtained from the contextual ef-
fects. In contrast, it is 0.83 for stiffness, 
suggesting that 83% improvement in 
stiffness is obtained from the contex-
tual effects. For chondroitin and lavage, 
100 % treatment effects in stiffness are 
contextual (Table II). 
The PCE also varies between diseases. 
It is slightly lower for pain in rheu-
matoid arthritis (PCE=0.63) (38) and 
fibromyalgia (PCE=0.60) (40). In addi-
tion, contextual effects are not only ob-
served in subjective outcomes such as 
pain, but also objective outcomes such 
as ESR (63%) and CRP (42%) (38).
The PCE is useful to guide clinical 
practice, as it informs the clinician 
concerning an overall strength of each 
treatment, proportion gained from the 
treatment and the context of the treat-
ment. It helps to fill the gap between 
RCTs and clinical practice; interpret 
evidence from trials more accurately, 
and encourage physicians to improve 
the quality of care (i.e. enhance/opti-
mise the context of therapy) when they 
deliver a treatment. 
Contextual enhancement
A number of contextual factors may be 
used to enhance contextual effects. Di 
Blasi et al. have classified them into 
five categories: patient characteristics, 
physician characteristics, patient-phy-
sician interactions, treatment charac-
teristics and environment (41). Some 
are easy to modify, whereas others are 
not. Suarez-Almazor et al. recently un-
dertook a two stage randomisation for 
communication style (high expectation 
vs. neutral expectation communica-
tion style) and acupuncture in knee OA 
(34). At the stage one, 560 patients with 
knee OA were randomly allocated to 3 
groups: high expectation communica-
tion, neutral expectation communica-
tion or waiting list. At the stage two, 
patients in the high or neutral expecta-
tion communication groups were ran-
domly allocated to either acupuncture 
or sham acupuncture. The treatments 
were given twice a week over 6 weeks. 
The outcomes were observed at week 0, 
4, 6 and 3 months and repeated meas-
ure analysis of variance was used to as-
sess the changes over time. The results 
showed that (a) all treatment groups 
Fig. 4. Proportion of the contextual effect in the treatment of osteoarthritis pain. 
Adapted from Zou et al.: Ann Rheum Dis 2016; 75: 1964-70 with permission. 
Fig. 3. Efficacy paradox. 
Table II. Proportion of the contextual effect in the treatment of osteoarthritis. 
Treatment                            PCE (95%CI)
   Pain Function Stiffness
Glucosamine  0.67 (0.53, 0.84) 0.64 (0.49, 0.82) 0.82 (0.63, 1.05)
Chondroitin 0.68 (0.55, 0.84) 0.63 (0.47, 0.85) 1.00 (0.77, 1.30)
Glucosamine+chondroitin 0.76 (0.62, 0.93) 0.85 (0.71, 1.02) 0.91 (0.72, 1.15)
Paracetamol 0.87 (0.73, 1.03) 0.92 (0.78, 1.09) 0.95 (0.72, 1.24)
NSAIDs 0.70 (0.65, 0.75) 0.64 (0.59, 0.70) 0.73 (0.67, 0.80)
Topical NSAIDs 0.85 (0.77, 0.93) 0.71 (0.58, 0.87) 0.93 (0.84, 1.03)
PEME 0.80 (0.64, 0.99) 0.63 (0.47, 0.84) 0.71 (0.43, 1.17)
Acupuncture 0.85 (0.74, 0.97) 0.85 (0.72, 1.00) 0.79 (0.66, 0.94)
IACS 0.47 (0.32, 0.70) 0.68 (0.40, 1.18) 0.83 (0.34, 2.04)
IAHA 0.82 (0.75, 0.90) 0.84 (0.74, 0.96) 0.88 (0.77, 1.00)
Lavage 0.91 (0.60, 1.37) 0.93 (0.62, 1.40) 1.00 (0.46, 2.16)
Overall 0.75 (0.72, 0.79) 0.71 (0.67, 0.75) 0.83 (0.79, 0.87)
IACS: intra-articular corticosteroid; IAHA: intra-articular hyaluronic acid; NSAIDs: non-steroidal 
anti-inflammatory drugs; PEMF: pulsed-electromagnetic field therapy.  
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experienced superior results compared 
to the waiting list group; (b) differences 
were seen between high and neutral ex-
pectation groups for pain reduction and 
satisfaction; (c) there was no difference 
between acupuncture and sham acu-
puncture. The study suggests that the 
analgesic effect of either treatment may 
be enhanced by positive/confident com-
munication of physicians. 
What are the key elements in the high 
and neutral expectation communication 
groups? The authors defined high ex-
pectation communication as confident 
treatment, using positive utterances 
such as “I think this will work for you”, 
“I’ve had a lot of success with treating 
knee pain”, and “Most of my patients 
get better”. A high expectation brochure 
was given to patients. The research co-
ordinator assisting with these patients 
was also trained to interact with a high 
expectation style. In contrast, neutral 
expectation was defined as presenting 
uncertainty about the treatment, using 
utterances such as “it may or may not 
work for you”, “It really depends on 
the patient”, and “We’re uncertain, and 
that’s why we are doing the study. A 
neutral expectation brochure was given 
to patients. The research co-ordinator 
for this group was trained to interact 
with a neutral style. 
These findings suggest that the contex-
tual effect may be enhanced by simply 
adding the non-specific treatment ele-
ments such as positive communication 
about the treatment. More research is 
needed to identify the key contextual 
elements that may be used in every 




Placebo effect is defined as a differ-
ence between placebo and no treatment 
(28, 33), whereas placebo response is 
defined as change from baseline in the 
placebo group (30). The former meas-
ures the specific treatment effect due to 
placebo, whereas the latter measures all 
changes related to the use of placebo in-
cluding the effect due to placebo (thera-
peutic ritual), effect due to being ob-
served (Hawthorn effect), regression to 
the mean, and outcome fluctuation due 
to the natural history of disease. Sever-
al alternative terms have been used for 
placebo effect, including non-specific 
treatment effect (42), meaning response 
(29) and context/contextual effect (43) 
(Fig. 2). Despite the caveats, placebo 
and placebo effect (or response) are 
still the most commonly used terms. I 
would like to suggest using “context of 
therapy” instead of placebo, and “con-
textual effect” instead of placebo effect 
in clinical practice, as these terms em-
phasise the importance of the context of 
treatment and encourage physicians to 
improve their care for patient. Placebo 
and placebo effect/response are useful 
and meaningful primarily in RCTs.
Obecalp
This is a word that reads reversely for 
placebo. It is one of many forms of pla-
cebo treatment accessible on the mar-
ket. Irrespective of the ethical challenge 
and debate for its benefits, placebo has 
been widely used by physicians and 
other health professionals all over the 
world. A systematic review of 22 sur-
veys across 12 countries shows that 
17 to 80% physicians and 51 to 100% 
nurses have ever prescribed placebo 
(44). The figure varies from country 
to country from 17% in Switzerland to 
99% in Sweden. It has been prescribed 
in the form of either pure placebos 
(such as obecalp), or impure placebos 
(such as antibiotics for viral infection). 
With conversion of the terminology 
from placebo/placebo effect to context/
contextal effect, physicians no longer 
need to prescribe the obecalp unethical-
ly, but to improve the patient-physician 
relationship. 
Nocebo effect
Placebo is not free from side effects. 
Adverse effects of placebo or context 
of therapy are defined as nocebo ef-
fects (45). In RCTs, nocebo effects 
depend substantially upon active treat-
ment (46), e.g. placebo to opioids 
causes more constipation, and placebo 
to colchicine causes more diarrhoea. In 
clinical practice, nocebo effects depend 
largely on patient – physician interac-
tions (47). For example, while “doctor’s 
touch” generally is beneficial, it could 
be harmful in some patients, simply be-
cause not everyone likes to be touched. 
It depends on individuals, culture and 
religion. Whom to touch, when to touch 
and where to touch remain questions to 
be answered through further clinical re-
search and observations. 
Conclusion 
OA is a common chronic painful joint 
condition with a long list of treatment 
options. On average about 75% of pain 
relief, 71% function improvement and 
83% stiffness improvement are gained 
from placebo or context of therapy. The 
contextual effect varies greatly between 
treatments, for example, from 47% 
with intra-articular steroid injection to 
91% with joint lavage for pain relief. 
The contextual effect may be enhanced 
through improvement of contextual 
elements such as patient-physician in-
teraction. Further research is required 
to identify the key contextual elements 
that can be delivered by physicians to 
enhance treatment effects in OA.
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